Baseline risk of hematologic malignancy at initiation of frontline PARP inhibitor maintenance for BRCA1/2-associated ovarian cancer
Poly(ADP-ribose) polymerase inhibitors (PARPi) are FDA approved as frontline maintenance for BRCA-associated advanced stage high-grade ovarian cancer (HGOC), having demonstrated an unprecedented improvement in relapse-free survival. Myelodysplastic syndrome (MDS) and acute myeloid leukemia (AML) are...
Saved in:
Main Authors: | Anastasia Navitski (Author), Duaa H. Al-Rawi (Author), Ying Liu (Author), Maria M. Rubinstein (Author), Claire F. Friedman (Author), Raajit K. Rampal (Author), Diana L. Mandelker (Author), Karen Cadoo (Author), Roisin E. O'Cearbhaill (Author) |
---|---|
Format: | Book |
Published: |
Elsevier,
2021-11-01T00:00:00Z.
|
Subjects: | |
Online Access: | Connect to this object online. |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Immunotherapy for recurrent or metastatic vulvar carcinoma: A case report and review of current guidelines
by: Aaron Praiss, et al.
Published: (2022) -
Shared decision making for patients with breast and gynecologic malignancies undergoing chemotherapy associated with persistent alopecia
by: Azael Freites-Martinez, et al.
Published: (2022) -
Efficacy and safety of PARP inhibitors for maintenance treatment of ovarian cancer, regardless of BRCA or HRD status: a comprehensive updated meta-analysis
by: Yanhui Li
Published: (2023) -
Primary osteosarcoma of the uterus with cardiac and pulmonary metastases
by: Cynthia Abraham, et al.
Published: (2015) -
Site-agnostic PARP-inhibitor maintenance therapy of advanced stage BRCA2-mutated gastric-type endocervical adenocarcinoma: A case report
by: Lauren Jill Tostrud, et al.
Published: (2024)